



# **Merseyside Inter Agency Drug Misuse Database**

**October– December 2006**

**Halton DAAT**

**Quarter 3 2006/07**

**Esther Shepherd, Martin Chandler,  
Jim McVeigh, Adam Marr and Paul Duffy**

**DRAFT REPORT**

The final version will be available on the IAD website

[www.cph.org.uk/iad](http://www.cph.org.uk/iad)

Contacts:

Martin Chandler

IAD Manager

Centre for Public Health

Faculty of Health & Applied Social Sciences

Liverpool John Moores University

Castle House

North Street

L3 2AY

(0151) 231 4531

[m.chandler@ljmu.ac.uk](mailto:m.chandler@ljmu.ac.uk)

Esther Shepherd

IAD Researcher

(0151) 231 4521

[e.shepherd@ljmu.ac.uk](mailto:e.shepherd@ljmu.ac.uk)

[www.cph.org.uk/iad](http://www.cph.org.uk/iad)

# Contents

	<u>Page</u>
<b>Introduction</b>	<b>1</b>
<b>Arrest Referral</b>	<b>3</b>
Table 1: Individuals assessed, by Gender and Age Group	
Table 2: Year to Date, by Gender and Age Group	
Table 3: Reported Main Drug(s) of Use, by Frequency of Use	
<b>Probation</b>	<b>5</b>
Table 4: Probation clients by Gender and Age Group	
Table 5: Year to Date, by Gender and Age Group	
Table 6: Reported Main Drug(s) of Use, by Frequency of Use	
<b>Syringe Exchange Services</b>	<b>7</b>
<b>Agency</b>	
Table 7: Individuals by Gender	
Table 8: Individuals by Gender: Steroid Users omitted	
Table 9: Individuals by Age Group	
Table 10: Individuals by Age Group: Steroid Users omitted	
Table 11: Gender by Age Group of Individuals	
Table 12: Gender by Age Group: Steroid Users omitted	
Table 13: Year to Date, by Gender & Age Group	
Table 14: Year to Date, by Gender & Age Group: Steroid Users omitted	
Table 15: Main Drug of Use for New Agency Syringe Exchange Clients, by Gender	
Table 16: Main Drug of Use, for New Agency Syringe Exchange Clients, by Age Group	
<b>Pharmacy</b>	<b>12</b>
Table 17: Individuals by Gender	
Table 18: Individuals by Age Group	
Table 19: Year to Date, by Gender & Age Group	
<b>Combined</b>	<b>13</b>
Table 20: Individuals in Syringe Exchange, by Gender	
Table 21: Individuals in Syringe Exchange, by Gender: Steroid Users omitted	
Table 22: Individuals in Syringe Exchange, by Age Group	
Table 23: Individuals in Syringe Exchange, by Age Group: Steroid Users omitted	
Table 24: Year to Date, by Gender & Age Group	
Table 25: Total Syringes Provided	

## **National Drug Treatment Monitoring System (NDTMS) 15**

Table 26: Individuals in contact with Treatment Services, by Gender

Table 27: Year to Date, by Gender

Table 28: Individuals in contact with Treatment Services, by Age Group

Table 29: Year to Date, by Age Group

Table 30: Ethnicity of Individuals in Contact with Treatment Services

Table 31: Individuals in contact with Treatment Services, by Main Drug of Use

## **Connexions 18**

Table 32: Individuals in Contact with Connexions, by Gender

Table 33: Year to Date, by Gender

Table 34: Individuals in Contact with Connexions, by Age

Table 35: Year to Date, by Age

Table 36: Individuals in Contact with Connexions by Drug/Alcohol Problem

Table 37: Year to Date, by Drug/Alcohol Problem

## **Combined Datasets 20**

Table 38: Total Problem Drug Users reported to the IAD, by Gender and Age Group

Table 39: Year to Date, by Gender & Age Group

## **Cross Matched Datasets 21**

Fig 1: Crossover between Agency Syringe Exchange and NDTMS datasets

Fig 2: Crossover between Pharmacy Syringe Exchange and NDTMS datasets

## Introduction

The Inter Agency Drug Misuse Database (IAD), established by Merseyside Drug (and Alcohol) Action Teams, Merseyside Police and the Public Health Sector (now Centre for Public Health) in 1997, supports the need for local information on drug misuse. In particular the IAD aims to:

- Provide comprehensive reporting of problem drug users' (PDUs') characteristics including a range of demographics and the types of drugs used.
- Reflect levels of service and intervention activity.
- Assist in D(A)AT's (and other responsible bodies) performance management.
- Facilitate the planning and development of services and interventions for PDUs.
- Identify gaps in service provision and delivery, as well as under-served groups as specified by the National Treatment Agency and Department of Health and by the Centre for Public Health, through interrogation of available data.
- Highlight changes in levels, demographics and characteristics of drug user populations.
- Report back to both individual D(A)ATs and service providers in the form of audits and quarterly reports as well as responding to ad hoc requests.
- Provide summary reporting on an annual basis.

To enable the above the IAD collects data from as many agencies in contact with drug users as possible and is continually seeking to expand the range and scope of data providers. Data are currently collected from criminal justice services, needle exchange schemes (both pharmacy and agency-based), the National Drug Treatment Monitoring System (NDTMS) and Connexions (young people).

### Data considerations

Analysis of data depends on the provision of attributable information. Each service provider records first and last initials, date of birth and gender, for each individual they record a contact with. The combination of these details provides an identifier (attributor) for each individual (e.g.: HF07/12/1974M). This is a nationally recognised system and allows individuals to be tracked through different service providers and across time whilst retaining an acceptable degree of anonymity. The attributor is essential to avoid double counting of individuals both within and across datasets, as well as enabling us to match across datasets. The D(A)AT referred to is the D(A)AT of contact unless otherwise stated.

The IAD will *only* be reporting attributable data for each dataset. In the past, report deadlines have been missed due to data arriving too late to be cleaned and analysed in time, or more often because the data requires a great deal of cleaning and validation before analysis. These reports are useful only if they can arrive within timelines useful to D(A)ATs (ie: in time for NTA quarterly submissions). For this reason, reports will now be sent out according to a strict timetable, with each quarter's report to be sent in the first week of the third month following the close of the reporting period. Any data that is missing or non-attributable will not be included in the report.

Year-to-Date figures will be provided for the current financial year, and will incorporate updated figures from previous quarters. The figures are calculated by aggregating successive quarterly datasets to omit double counting of those who present to services in each quarter. Year-to-Date data will be the most accurate reflection of annual service activity and will override previous quarterly data.

The Centre for Public Health will continue to work closely with service providers and D(A)ATs in order to improve both the timeliness and quality of monitoring data provided to the IAD. Many service providers are turning to electronic recording of data and it is hoped this will vastly improve the quality of the data as systems improve.

## ARREST REFERRAL (AR)

Quarter 3 (2006/07)

### Introduction

Raw data are provided by the Drug Interventions Programme (DIP) Team based at the Centre for Public Health, Liverpool John Moores University. The data supplied are for validated contacts within specified D(A)AT areas and are aggregated to one person per D(A)AT area. Individuals may therefore appear more than once within the final dataset if they have been seen in more than one D(A)AT area, but only once for each D(A)AT area within the reporting period.

**Table 1: Individuals assessed, by Gender & Age Group**

Gender	n	%
Male	17	73.9
Female	6	26.1
Age Group		
Under 18	1	4.3
18-19	2	8.7
20-24	2	8.7
25-29	7	30.4
30-34	4	17.4
35-39	5	21.7
40-44	2	8.7
45+	0	0
<b>Total</b>	<b>23</b>	<b>100</b>

**Table 2: Year to Date, by Gender & Age Group**

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	2	3.0	0	0	2	2.4
18-19	2	3.0	2	12.5	4	4.9
20-24	10	15.2	1	6.3	11	13.4
25-29	16	24.2	3	18.8	19	23.2
30-34	14	21.2	4	25.0	18	22.0
35-39	17	25.8	5	31.3	22	26.8
40-44	4	6.1	1	6.3	5	6.1
45+	1	1.5	0	0	1	1.2
<b>Total</b>	<b>66</b>	<b>100</b>	<b>16</b>	<b>100</b>	<b>82</b>	<b>100</b>

**Table 3: Reported Main Drug(s) of Use, by Frequency of Use**

Drug of Use	Daily	Weekly
Amphetamines	2	0
Benzodiazepines	0	0
Cannabis	3	0
Crack	8	0
Cocaine	2	0
Ecstasy	0	2
Heroin	15	0
Methadone	1	0

**NB:** The complexity of the drug profiles reported through arrest referral is such that we have decided the best way of reporting the data is to provide figures for the number of people reporting Daily or Weekly use of each drug. Where “Main drug” is provided in the original data it does not always match the other substances reported as being used daily; consequently, this method of reporting should provide a more accurate picture of drug use as reported through Arrest Referral rather than simply stating the “Main Drug”. However it should be noted that some people may report several drugs being used and will therefore be counted in the figures for each drug they report. For this reason totals are not provided.

**PROBATION**

Quarter 3 (2006/07)

**Introduction**

Data is provided by Cheshire Probation Services. Data relates to individuals reported through OASys with a reported substance use problem. Individuals who are on ASROs or similar treatment orders are reported to NDTMS.

**NOTE:** Probation figures are based on D(A)AT of Residence, NOT D(A)AT of contact as with other datasets.

**Table 4: Probation Clients by Gender and Age Group**

Gender	n	%
Male	40	78.4
Female	11	21.6
Age Group		
Under 18	0	0
18-19	4	7.8
20-24	14	27.5
25-29	12	23.5
30-34	6	11.8
35-39	7	13.7
40-44	4	7.8
45+	4	7.8
<b>Total</b>	<b>51</b>	<b>100</b>

**Table 5: Year to Date, by Gender & Age Group**

Age Group	Gender				Total in Age Group	
	Male		Female		n	%
	n	%	n	%		
Under 18	0	0	0	0	0	0
18-19	19	15.2	2	9.5	21	14.4
20-24	36	28.8	3	14.3	39	26.7
25-29	19	15.2	5	23.8	24	16.4
30-34	11	8.8	4	19.0	15	10.3
35-39	13	10.4	2	9.5	15	10.3
40-44	9	7.2	4	19.0	13	8.9
45+	18	14.4	1	4.8	19	13.0
<b>Total</b>	<b>125</b>	<b>100</b>	<b>21</b>	<b>100</b>	<b>146</b>	<b>100</b>

**Table 6: Reported Main Drug(s) of Use, by Frequency of Use**

Drug of Use	Daily	Weekly
Amphetamines	0	0
Benzodiazepines	1	0
Cannabis	3	5
Crack	3	0
Cocaine	0	0
Hallucinogens	0	1
Heroin	7	2
Methadone	5	0

N.B: Table 6 shows the number of people reporting daily or weekly use of specific drugs. This is to reflect reporting of polydrug use through Probation data. No totals are given as clients can report daily or weekly use of more than one drug and may therefore be double counted between drugs.

#### **ASROs**

- 11 ASROs were commenced during Q2 and 7 during Q3 0607
- 13 Individuals commenced ASROs between July-December 2006
- 10 ASROs were terminated during Q2 and 13 during Q3 0607
- 15 individuals had their ASROs' terminated between July- December 2006

## SYRINGE EXCHANGE SERVICES

Quarter 3 (2006/07)

### Introduction

Data are collected directly from syringe exchange providers. Analysis of syringe exchange data allows performance monitoring of harm reduction services at both D(A)AT and service provider level.

### AGENCY SYRINGE EXCHANGE

**Table 7: Individuals by Gender**

<b>New Clients</b>	<b>n</b>	<b>%</b>
Male	28	87.5
Female	4	12.5
<i>Total</i>	<i>32</i>	<i>100</i>
<b>All Clients</b>		
Male	113	89.7
Female	13	10.3
<i>Total</i>	<i>126</i>	<i>100</i>

**Table 8: Individuals by Gender: Steroids Users Omitted**

<b>New Clients</b>	<b>n</b>	<b>%</b>
Male	12	75.0
Female	4	25.0
<i>Total</i>	<i>16</i>	<i>100</i>
<b>All Clients</b>		
Male	47	78.3
Female	13	21.7
<i>Total</i>	<i>60</i>	<i>100</i>

**Table 9: Individuals by Age Group**

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0	0	0
18-19	1	3.1	2	1.6
20-24	8	25.0	24	19.0
25-29	5	15.6	24	19.0
30-34	7	21.9	26	20.6
35-39	9	28.1	27	21.4
40-44	1	3.1	14	11.1
45+	1	3.1	9	7.1
<b>Total</b>	<b>32</b>	<b>100</b>	<b>126</b>	<b>100</b>

**Table 10: Individuals by Age Group: Steroid Users omitted**

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0	0	0
18-19	0	0	0	0
20-24	1	6.3	3	5.0
25-29	2	12.5	8	13.3
30-34	3	18.8	11	18.3
35-39	8	50.0	20	33.3
40-44	1	6.3	10	16.7
45+	1	6.3	8	13.3
<b>Total</b>	<b>16</b>	<b>100</b>	<b>60</b>	<b>100</b>

Table 11: Gender by Age Group of Individuals

Age Group	Gender			
	Male		Female	
	n	%	n	%
Under 18	0	0	0	0
18-19	2	1.8	0	0
20-24	23	20.4	1	7.7
25-29	20	17.7	4	30.8
30-34	24	21.2	2	15.4
35-39	24	21.2	3	23.1
40-44	14	12.4	0	0
45+	6	5.3	3	23.1
<b>Total</b>	<b>113</b>	<b>100</b>	<b>13</b>	<b>100</b>

Table 12: Gender by Age Group: Steroid Users omitted

Age Group	Gender			
	Male		Female	
	n	%	n	%
Under 18	0	0	0	0
18-19	0	0	0	0
20-24	2	4.3	1	7.7
25-29	4	8.5	4	30.8
30-34	9	19.1	2	15.4
35-39	17	36.2	3	23.1
40-44	10	21.3	0	0
45+	5	10.6	3	23.1
<b>Total</b>	<b>47</b>	<b>100</b>	<b>13</b>	<b>100</b>

Table 13: Year to Date, by Gender &amp; Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	1	0.3	0	0	1	0.3
18-19	10	3.3	0	0	10	3.2
20-24	78	26.0	1	5.9	79	24.9
25-29	58	19.3	6	35.3	64	20.2
30-34	66	22.0	3	17.6	69	21.8
35-39	42	14.0	3	17.6	45	14.2
40-44	25	8.3	1	5.9	26	8.2
45+	20	6.7	3	17.6	23	7.3
<b>Total</b>	300	100	17	100	317	100

Table 14: Year to Date, by Gender &amp; Age Group: Steroid Users Omitted

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	0	0	0	0	0	0
18-19	1	1.1	0	0	1	0.9
20-24	7	7.4	1	5.9	8	7.2
25-29	12	12.8	6	35.3	18	16.2
30-34	26	27.7	3	17.6	29	26.1
35-39	22	23.4	3	17.6	25	22.5
40-44	16	17.0	1	5.9	17	15.3
45+	10	10.6	3	17.6	13	11.7
<b>Total</b>	94	100	17	100	111	100

**Table 15: Main Drug of Use for New Agency Syringe Exchange Clients, by Gender**

Drug of Use	Gender			
	Male		Female	
	n	%	n	%
Amphetamines	0	0	1	25.0
Cocaine	0	0	0	0
Crack	0	0	0	0
Heroin	0	0	0	0
Methadone	4	14.3	2	50.0
Steroids	16	57.1	0	0
Various/Unknown	8	28.5	1	25.0
<b>Total</b>	<b>28</b>	<b>100</b>	<b>4</b>	<b>100</b>

**Please Note:** Due to changes in reporting methods we will now only report drug of use for new clients. Information on drug of use for all clients is available on request.

**Table 16: Main Drug of Use for New Agency Syringe Exchange Clients, by Age Group**

Age Group	Amphetamine		Methadone		Steroids		Various/ Unknown	
	n	%	n	%	n	%	n	%
Under 18	0	0	0	0	0	0	0	0
18-19	0	0	0	0	1	100	0	0
20-24	0	0	0	0	7	87.5	1	12.5
25-29	0	0	1	20.0	3	60.0	1	20.0
30-34	0	0	2	28.6	4	57.1	1	14.3
35-39	1	11.1	2	22.2	1	11.1	5	55.5
40-44	0	0	1	100	0	0	0	0
45+	0	0	0	0	0	0	1	100
<b>Total*</b>	<b>1</b>	<b>3.1</b>	<b>6</b>	<b>18.8</b>	<b>16</b>	<b>50.0</b>	<b>9</b>	<b>21.9</b>

\* % Totals are by Drug, not Age Group.

## PHARMACY SYRINGE EXCHANGE

**Table 17: Individuals by Gender**

<b>New Clients</b>	<b>n</b>	<b>%</b>
Male	25	92.6
Female	2	7.4
<i>Total</i>	<i>27</i>	<i>100</i>
<b>All Clients</b>		
Male	59	90.8
Female	6	9.2
<i>Total</i>	<i>65</i>	<i>100</i>

**Table 18: Individuals by Age Group**

<b>Age Group</b>	<b>New Clients</b>		<b>All Clients</b>	
	<b>n</b>	<b>%</b>	<b>n</b>	<b>%</b>
Under 18	0	0	0	0
18-19	0	0	0	0
20-24	8	29.6	12	18.5
25-29	8	29.6	13	20.0
30-34	4	14.8	18	27.7
35-39	2	7.4	7	10.8
40-44	2	7.4	8	12.3
45+	3	11.1	7	10.8
<i>Total</i>	<i>27</i>	<i>100</i>	<i>65</i>	<i>100</i>

**Table 19: Year to Date, by Gender & Age Group**

<b>Age Group</b>	<b>Gender</b>				<b>Total in Age Group</b>	
	<b>Male</b>		<b>Female</b>			
	<b>n</b>	<b>%</b>	<b>n</b>	<b>%</b>	<b>n</b>	<b>%</b>
Under 18	0	0	0	0	0	0
18-19	0	0	0	0	0	0
20-24	20	18.3	2	10.5	22	17.2
25-29	21	19.3	6	31.6	27	21.1
30-34	27	24.8	5	26.3	32	25.0
35-39	17	15.6	3	15.8	20	15.6
40-44	13	11.9	2	10.5	15	11.7
45+	11	10.1	1	5.3	12	9.4
<i>Total</i>	<i>109</i>	<i>100</i>	<i>19</i>	<i>100</i>	<i>128</i>	<i>100</i>

## COMBINED PHARMACY AND AGENCY SYRINGE EXCHANGE

Analyses here are based on an aggregated combination of Agency and Pharmacy-based datasets for the reporting period. Data are aggregated by attributor and D(A)AT of Agency to one person per D(A)AT area.

**Table 20: Individuals in Syringe Exchange, by Gender**

<b>New Clients</b>	<b>n</b>	<b>%</b>
Male	53	89.8
Female	6	10.2
<i>Total</i>	<i>59</i>	<i>100</i>
<b>All Clients</b>		
Male	161	89.9
Female	18	10.1
<b>Total</b>	<i>179</i>	<i>100</i>

**Table 21: Individuals in Syringe Exchange, by Gender: Steroid Users Omitted\***

<b>New Clients</b>	<b>n</b>	<b>%</b>
Male	36	85.7
Female	6	14.3
<i>Total</i>	<i>42</i>	<i>100</i>
<b>All Clients</b>		
Male	95	84.1
Female	18	15.9
<b>Total</b>	<i>113</i>	<i>100</i>

\*Only known steroid users, based on Agency SES data, have been omitted.

**Table 22: Individuals in Syringe Exchange, by Age Group**

<b>Age Group</b>	<b>New Clients</b>		<b>All Clients</b>	
	<b>n</b>	<b>%</b>	<b>n</b>	<b>%</b>
Under 18	0	0	0	0
18-19	1	1.7	2	1.1
20-24	16	27.1	36	20.1
25-29	13	22.0	35	19.6
30-34	11	18.6	40	22.3
35-39	11	18.6	31	17.3
40-44	3	5.1	20	11.2
45+	4	6.8	15	8.4
<b>Total</b>	<i>59</i>	<i>100</i>	<i>179</i>	<i>100</i>

**Table 23: Individuals in Syringe Exchange by Age Group: Steroid Users Omitted**

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0	0	0
18-19	0	0	0	0
20-24	9	21.4	15	13.3
25-29	9	21.4	19	16.8
30-34	7	16.7	25	22.1
35-39	10	23.8	24	21.2
40-44	3	7.1	16	14.2
45+	4	9.5	14	12.4
<b>Total</b>	<b>42</b>	<b>100</b>	<b>113</b>	<b>100</b>

**Table 24: Year to Date, by Gender & Age Group**

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	1	0.3	0	0	1	0.2
18-19	10	2.6	0	0	10	2.4
20-24	97	25.4	2	6.5	99	24.0
25-29	76	19.9	10	32.3	86	20.8
30-34	84	22.0	8	25.8	92	22.3
35-39	51	13.4	5	16.1	56	13.6
40-44	35	9.2	3	9.7	38	9.2
45+	28	7.3	3	9.7	31	7.5
<b>Total</b>	<b>382</b>	<b>100</b>	<b>31</b>	<b>100</b>	<b>413</b>	<b>100</b>

**Table 25: Total Syringes Provided**

	This Quarter	Year to Date
Barrels	10955	31326
Needles	18901	54620

**NB:** We will no longer be reporting needle returns as it is not possible to accurately calculate them from the data available. Total Syringes include exchanges by non-attributable individuals.

## National Drug Treatment Monitoring System (NDTMS)

Quarter 3 (2006/07)

### Background

The NDTMS is the official method for measuring the extent and nature of structured drug treatment in England and Wales. The system is commissioned by the NTA and is operated through nine regional centres – corresponding to the nine government offices for the regions.

Data here are aggregated to one individual per D(A)AT. Individuals presenting in more than one D(A)AT within the quarter's time period will therefore be represented more than once in the original data. The D(A)AT referred to is D(A)AT of treatment.

### New Clients

Figures presented here for "new" clients are calculated using the triage date. Those individuals triaged within the reporting period are taken as new clients for this report. However, it should be noted that these individuals may have been triaged, or in contact with treatment services, before this period.

**Table 26: Individuals in Contact with Treatment Services, by Gender**

<b>New Clients</b>	n	%
Male	48	69.6
Female	21	30.4
<i>Total</i>	<i>69</i>	<i>100</i>
<b>All Clients</b>		
Male	519	71.9
Female	203	28.1
<i>Total</i>	<i>722</i>	<i>100</i>

**Table 27: Year to Date, by Gender**

<b>New Clients</b>	n	%
Male	125	76.2
Female	39	23.8
<i>Total</i>	<i>164</i>	<i>100</i>
<b>All Clients</b>		
Male	531	72.2
Female	204	27.8
<i>Total</i>	<i>735</i>	<i>100</i>

**Table 28: Individuals in Contact with Treatment Services, by Age Group**

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	2	2.9	49	6.8
18-19	1	1.4	28	3.9
20-24	5	7.2	63	8.7
25-29	19	27.5	125	17.3
30-34	17	24.6	167	23.1
35-39	13	18.8	144	19.9
40-44	7	10.1	95	13.2
45+	5	7.2	51	7.1
<b>Total</b>	<b>69</b>	<b>100</b>	<b>722</b>	<b>100</b>

**Table 29: Year to Date, by Age Group**

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	34	20.7	65	8.8
18-19	6	3.7	23	3.1
20-24	21	12.8	106	14.4
25-29	29	17.7	167	22.7
30-34	32	19.5	173	23.5
35-39	22	13.4	114	15.5
40-44	13	7.9	50	6.8
45+	7	4.3	37	5.0
<b>Total</b>	<b>164</b>	<b>100</b>	<b>735</b>	<b>100</b>

Table 30: Ethnicity of Individuals in Contact with Treatment Services

Ethnicity	New Clients		All Clients	
	n	%	n	%
White British	68	98.6	708	98.6
White Irish	1	1.5	3	0.4
Other White	0	0	1	0.1
White & Black Caribbean	0	0	3	0.4
White & Black African	0	0	2	0.3
White & Asian	0	0	0	0
Other Mixed	0	0	0	0
Other Asian	0	0	0	0
Caribbean	0	0	1	0.1
African	0	0	0	0
Other Black	0	0	1	0.1
Chinese	0	0	0	0
Other	0	0	0	0
Unknown	0	0	3	0.4
<b>Total</b>	<b>69</b>	<b>100</b>	<b>722</b>	<b>100</b>

Table 31: Individuals in Contact with Treatment Services, by Main Drug of Use

Drug of Use	New Clients		All Clients	
	n	%	n	%
Amphetamine	3	4.4	34	4.7
Benzodiazepine	0	0	2	0.3
Ecstasy	0	0	5	0.7
Cannabis	7	10.1	105	14.5
Cocaine	9	13.0	85	11.8
Crack	5	7.3	33	4.6
Hallucinogens	0	0	1	0.1
Heroin	35	50.7	380	52.6
Methadone	9	13.0	60	8.3
Other Opiates	1	1.5	12	1.7
Other/Unknown	0	0	5	0.7
<b>Total</b>	<b>69</b>	<b>100</b>	<b>722</b>	<b>100</b>

## CONNEXIONS

### Quarter 3 (2006/07)

#### Background

Connexions provide a support service for young people, aged 13-19. The Greater Merseyside Connexions Partnership provides data presented here.

**Table 32: Individuals in Contact with Connexions, by Gender**

Gender	n	%
Male	10	47.6
Female	11	52.4
<b>Total</b>	<b>21</b>	<b>100</b>

**Table 33: Year to Date, by Gender**

Gender	n	%
Male	16	53.3
Female	14	46.7
<b>Total</b>	<b>30</b>	<b>100</b>

**Table 34: Individuals in Contact with Connexions, by Age**

Age Group	n	%
16	6	28.6
17	9	42.9
18	4	19.0
19	2	9.5
<b>Total</b>	<b>21</b>	<b>100</b>

**Table 35: Year to Date, by Age**

Age Group	n	%
16	6	20.0
17	14	46.7
18	4	13.3
19	6	20.0
<b>Total</b>	<b>30</b>	<b>100</b>

**Table 36: Individuals in Contact with Connexions by Drug/Alcohol Problem**

Substance	n	%
Alcohol/Other*	4	19.0
Drugs	17	81.0
<b>Total</b>	<b>21</b>	<b>100</b>

\*"Other" is generally used to refer to solvents although this is not necessarily always the case.

**Table 37: Year to Date, by Drug/Alcohol problem**

Substance	n	%
Alcohol/Other*	7	23.4
Drugs	23	76.6
<b>Total</b>	<b>30</b>	<b>100</b>

\*"Other" is generally used to refer to solvents although this is not necessarily always the case.

## COMBINED DATASETS

Quarter 3 (2006/07)

### Introduction

Data presented here are drawn from a combination of datasets relating to Arrest Referrals, Probation, Syringe Exchange (Agency and Pharmacy), NDTMS and Connexions. The combined data are aggregated on attributor and D(A)AT area of intervention (except Probation, which is based on residence), to produce overall figures for numbers of individuals in contact with services reporting to the IAD. Figures presented here will not necessarily reflect the combined totals of data presented earlier as duplicate attributors are removed. These figures should not be taken as a measure of prevalence of problem drug users, but reflect the total number of problem drug users in contact with a range of agencies. Further information on the processes of data manipulation, aggregation and analysis is available from the IAD Manager.

**Table 38: Total Problem Drug Users reported to the IAD, by Gender and Age Group**

Gender	n	%
Male	679	74.9
Female	228	25.1
Age Group		
Under 18	77	8.5
18-19	34	3.7
20-24	140	15.4
25-29	197	21.7
30-34	203	22.4
35-39	136	15.0
40-44	71	7.8
45+	49	5.4
<b>Total</b>	<b>907</b>	<b>100</b>

**Table 39: Year to Date, by Gender and Age Group**

Age Group	Gender				Total in Age Group	
	Male		Female		n	%
	n	%	n	%		
Under 18	62	6.2	21	8.3	83	6.6
18-19	51	5.1	13	5.1	64	5.1
20-24	211	21.2	35	13.8	246	19.7
25-29	200	20.1	60	23.6	260	20.8
30-34	207	20.8	58	22.8	265	21.2
35-39	140	14.0	33	13.0	173	13.8
40-44	70	7.0	17	6.7	87	7.0
45+	56	5.6	17	6.7	73	5.8
<b>Total</b>	<b>997</b>	<b>100</b>	<b>254</b>	<b>100</b>	<b>1251</b>	<b>100</b>

## CROSS-MATCHED DATASETS


Quarter 3 (2006/07)

Data are shown for the crossover between each type of Syringe Exchange and NDTMS, separately, during the current reported quarter. For the purposes of this analysis, known steroid users were removed as they are less likely to be accessing structured drug treatment.

For methodological reasons the crossover between all three datasets will no longer be reported. Further information is available from the IAD manager if required.

NB: Numbers in brackets refer to the total reported for that service type, with steroid users omitted. These include the numbers appearing on the crossover sections. Analyses for the crossover areas are based on D(A)AT of Syringe Exchange site.

**Fig 1: Crossover between Agency Syringe Exchange and NDTMS datasets**



**Fig 2: Crossover between Pharmacy Syringe Exchange and NDTMS datasets**

